You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Validation of a Novel Fungicidal Approach for Cryptococcal Meningitis

    SBC: Minnetronix Medical, Inc.            Topic: NIAID

    ABSTRACT When Cryptococcus is manifested as cryptococcal meningitis (CM), it creates a large burden of mortality and morbidity to the patient and is very difficult for the clinician to treat. There are now an estimated 2600-7800 US cases and 400,000 cases of CM worldwide annually, with estimated mortality of 15-50% per year. CM is caused when Cryptococcus neoformans, a basidiomycete fungal pathoge ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Validation of a salivary miRNA diagnostic test for autism spectrum disorder

    SBC: Quadrant Biosciences Inc.            Topic: 103

    Autism spectrum disorder (ASD) is a continuum of neurodevelopmental characteristics that includes deficits in communication and social interaction, as well as restrictive, repetitive interests and behaviors. ASD is an increasing public health concern, with about 1 in 45 American children diagnosed with ASD in 2014, a 10-fold increase in prevalence over the past 40 years. The effect of ASD on both ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: LEUKOGENE THERAPEUTICS INC            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Novel SCD1 inhibitors for treatment of cancer

    SBC: MODULATION THERAPEUTICS, INC.            Topic: 102

    Project Summary Metabolic reprogramming plays a critical role in carcinogenesisin part due its ability to promote immune suppressive properties within tumorsHoweverit is unclear whether inhibition of fatty acid metabolism in tumors affects their immunogenicityHerewe show for the first time that inhibition of stearoyl CoA desaturaseSCDthe rate limiting enzyme involved in fatty acid synthesis conver ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Clinical Translation of an Anti-Metastatic Antibody for Breast Cancer Therapy

    SBC: FOR-ROBIN, INC.            Topic: 102

    DESCRIPTION provided by applicant Translational studies are proposed to support the continued development of the JAA F antibody based therapy to address the critical need for a safe and effective treatment for metastatic breast cancer including triple negative breast cancers Building on the success of our Phase I project the overarching objectives of the Phase II application are to advanc ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  6. Validation of Novel Therapeutic Approach for Leptomeningeal Metastases

    SBC: Minnetronix Medical, Inc.            Topic: 102

    ABSTRACT Leptomeningeal Metastases (LM) is a condition in which tumor cells from a primary tumor metastasize, invade the subarachnoid space (SAS) and spread throughout the cerebrospinal fluid (CSF), resulting in seeding along the meninges, brain and spinal cord. LM represents a devastating event of cancer progression. There are 30,000 cases annually and currently no cure, with average survival of ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Stroke Treatment by Chemically-induced Hypothermia

    SBC: JT Pharmaceuticals, Inc.            Topic: 101

    DESCRIPTION provided by applicant Stroke is a leading cause of human death and disability in the United States while clinical therapy for acute stroke is limited and unsatisfactoy The many failures in clinical trials strongly endorse the idea that to battle this multifaceted bran disorder novel strategies that target multiple cell types and different mechanisms are needed to achieve therapeut ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  8. Noom Monitor for Binge Eating

    SBC: Noom, Inc.            Topic: 104

    DESCRIPTION provided by applicant Binge eating is a core maladaptive behavior characteristic of several forms of eating pathology including bulimia nervosa BN and binge eating disorder BED These chronic conditions affect approximately percent of the population and cause significant psychosocial and physical impairment However a number of barriers prevent the implementation of effecti ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  9. Live-Cell Fluorescence Lifetime FRET Assays for HTS

    SBC: Fluorescence Innovations, Inc.            Topic: R42

    DESCRIPTION provided by applicant We seek to develop and commercialize a powerful technology platform to increase dramatically the effectiveness of drug discovery using high throughput screening HTS based on fluorescence lifetime FLT readouts of FRET in live cells This breakthrough is enabled by a combination of two complementary and synergistic technologies fluorescent biosensor engineer ...

    STTR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  10. Electronic Optimization of Stem Cell Derived Human Cardiac Myocytes

    SBC: Cytocybernetics Inc            Topic: NHLBI

    Project Summary As part of the FDA approval process for novel therapeutic drugssafety screening demonstrating that the candidate drug does not have deleterious effects on the human cardiac action potential is requiredHealthy human heart cells are not available for such preclinical drug testingThere is currently no consensus on the best experimental approach to provide the most efficienteconomicala ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government